Jazz Pharmaceuticals (JAZZ) 44th Annual J.P. Morgan Healthcare Conference summary

2025 accomplishments and performance

• Achieved record total revenue, nearing the top end of guidance, and increased market value by over $2.8 billion.

• Epidiolex and Xywav each surpassed $1 billion in sales, with Epidiolex reaching blockbuster status.

• Launched Medaso/Modeyso, the first and only drug for H3K27M-mutant DMG, exceeding launch expectations and generating nearly $50 million in 2025 revenue.

• Zepzelca and Ziihera (zanidatamab) delivered practice-changing clinical results, positioning them as new standards of care in their indications.

• Resolved all major litigation, enhancing IP durability for key assets and delaying generic competition until the late 2030s.

Strategic evolution and future focus

• Refined strategy to focus on rare diseases in sleep, epilepsy, oncology, and new rare therapeutic areas, targeting high unmet need and favorable regulatory dynamics.

• Plans to build multiple billion-dollar franchises using internal discovery, disciplined corporate development, and leveraging 20+ years of expertise.

• Emphasis on customer centricity, digital/AI capabilities, and all employees to be trained in AI by year-end.

• Will deprioritize broad neuroscience indications, focusing on rare disease opportunities with potential for broader applicability if discovered.

• CEO transition completed successfully, supporting strategic continuity.

Research and development highlights

• Zanidatamab (Ziihera) showed unprecedented survival in HER2-positive GEA, outperforming Herceptin and expected to become the new standard of care.

• sBLA submission for zanidatamab in 1L GEA planned for first half of the year, with potential approval and launch later in the year.

• Multiple indication expansion opportunities for zanidatamab, including breast, gastric, CRC, and NSCLC.

• Dordaviprone (Modeyso) Phase 3 ACTION trial ongoing, with interim data expected late 2026/early 2027.

• Jazz-discovered molecules expected to enter the clinic soon, with a focus on validated mechanisms and rare disease targets.